eCite Digital Repository

IMI 2021 yearly digest

Citation

Jong, M and Jonas, JB and Wolffsohn, JS and Berntsen, DA and Cho, P and Clarkson-Townsend, D and Flitcroft, DI and Gifford, KL and Haarman, AEG and Pardue, MT and Richdale, K and Sankaridurg, P and Tedja, MS and Wildsoet, CF and Bailey-Wilson, JE and Guggenheim, JA and Hammond, CJ and Kaprio, J and MacGregor, S and Mackey, DA and Musolf, AM and Klaver, CCW and Verhoeven, VJM and Vitart, V and Smith, EL, IMI 2021 yearly digest, Investigative Ophthalmology and Visual Science, 62, (5) pp. 1-22. ISSN 0146-0404 (2021) [Refereed Article]


Preview
PDF (Published version)
934Kb
  

Copyright Statement

Copyright 2021 The Authors. This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License (https://creativecommons.org/licenses/by-nc-nd/4.0/)

DOI: doi:10.1167/iovs.62.5.7

Abstract

Purpose: The International Myopia Institute (IMI) Yearly Digest highlights new research considered to be of importance since the publication of the first series of IMI white papers.

Methods: A literature search was conducted for articles on myopia between 2019 and mid-2020 to inform definitions and classifications, experimental models, genetics, interventions, clinical trials, and clinical management. Conference abstracts from key meetings in the same period were also considered.

Results: One thousand articles on myopia have been published between 2019 and mid-2020. Key advances include the use of the definition of premyopia in studies currently under way to test interventions in myopia, new definitions in the field of pathologic myopia, the role of new pharmacologic treatments in experimental models such as intraocular pressure-lowering latanoprost, a large meta-analysis of refractive error identifying 336 new genetic loci, new clinical interventions such as the defocus incorporated multisegment spectacles and combination therapy with low-dose atropine and orthokeratology (OK), normative standards in refractive error, the ethical dilemma of a placebo control group when myopia control treatments are established, reporting the physical metric of myopia reduction versus a percentage reduction, comparison of the risk of pediatric OK wear with risk of vision impairment in myopia, the justification of preventing myopic and axial length increase versus quality of life, and future vision loss.

Conclusions: Large amounts of research in myopia have been published since the IMI 2019 white papers were released. The yearly digest serves to highlight the latest research and advances in myopia.

Item Details

Item Type:Refereed Article
Research Division:Biomedical and Clinical Sciences
Research Group:Ophthalmology and optometry
Research Field:Ophthalmology
Objective Division:Health
Objective Group:Clinical health
Objective Field:Treatment of human diseases and conditions
UTAS Author:Mackey, DA (Professor David Mackey)
ID Code:146863
Year Published:2021
Web of Science® Times Cited:6
Deposited By:Menzies Institute for Medical Research
Deposited On:2021-09-30
Last Modified:2021-11-18
Downloads:6 View Download Statistics

Repository Staff Only: item control page